key: cord-0919025-xdpqxxqh
authors: Luczkowiak, J.; Rivas, G.; Labiod, N.; Lasala, F.; Rolo, M.; Lora-Tamayo, J.; Mancheno-Losa, M.; Rial-Crestelo, D.; Folgueira, M. D.; Delgado, R.
title: Potency and Breadth of Neutralization after 3 doses of mRNA vaccines in COVID-19 Convalescent and Naive individuals
date: 2022-03-20
journal: nan
DOI: 10.1101/2022.03.17.22272557
sha: f6eecbc8db53fc6331eee110c5343206db81a66a
doc_id: 919025
cord_uid: xdpqxxqh

Third doses of mRNA COVID-19 vaccines induced a significant increase in neutralizing potency and breadth in naive individuals comparable with convalescents who restored levels after the first two doses. These results suggest a limit to elicit neutralization in the number of stimuli by infection or vaccination with ancestral SARS-CoV-2 sequences

convalescents who restored levels after the first two doses. These results 28 suggest a limit to elicit neutralization in the number of stimuli by infection or 29 vaccination with ancestral SARS-CoV-2 sequences 30

Background 31 32

The implementation of COVID-19 vaccines has been one of the main tools for 33 pandemic control. The contraction of humoral response after vaccination and 34 the emergence of the different SARS-COV-2 variants of concern (VoC), along is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2022. ; https://doi.org/10.1101/2022.03.17.22272557 doi: medRxiv preprint a correlation with results obtained with RBD-binding total antibodies at the 105 same time points in both groups of participants ( Figure 2 ). The neutralizing 106 titer against SARS-CoV-1 was as expected low for naïve individuals after the 107 first two doses and also increased significantly after the third dose (GMT 397 108 IU/mL) but this level was significantly lower than the achieved in the 109 convalescent group (GMT 768 IU/mL) (p=0.018). (Figure 1) . 110

A third dose of an mRNA vaccine resulted as expected in an increase of the 113 neutralizing response whose potency and breadth were more significant in 114 naïve individuals as compared with COVID-19 convalescent patients. This later 115 group, as described (7) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2022. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2022. ; https://doi.org/10.1101/2022.03.17.22272557 doi: medRxiv preprint

We are greatly thankful to all participants in the Solidarity II cohort study 225 226 227 228 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2022. ; https://doi.org/10.1101/2022.03.17.22272557 doi: medRxiv preprint

Horizon Europe Framework programme: Project EPIC-CROWN-2 ID: 218 101046084 and by Fundación Caixa-Health Research

Plasma Neutralization of the SARS-CoV-2 Omicron Variant

Three exposures to the spike protein of SARS-CoV-2 by either infection or 238 vaccination elicit superior neutralizing immunity to all variants of concern

Spikevax: EMA. EMA 241 recommendation on booster

Neutralizing Response Against SARS-CoV-2 Variants 8 Months After 245

BNT162b2 Vaccination in Naive and COVID-19-Convalescent Individuals. The 246 Journal of Infectious Diseases